EANS-News: Epigenomics CEO to give Corporate Update at Investor Conferences in Europe and U.S.

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

Press release, Berlin, Germany, and Seattle, WA, U.S.A., September 3,
2010 (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), a
cancer molecular diagnostics company informed, that Geert W. Nygaard,
CEO Epigenomics AG, will provide a corporate update at two upcoming
Investor conferences in Zurich and New York.

At the German Healthcare Conference in Zurich and the UBS Global Life
Sciences Conference in New York he will inform the investment
community on the progress the Company made in commercializing its
molecular diagnostic products for colon and lung cancer and provide
an outlook on plans and activities regarding FDA clearance and
commercialization of the Company's colorectal cancer blood test Epi
proColon in the U.S.A.

Conference Details:

German Healthcare Conference Presentation on September 8, 2010 at
3:45 p.m. CET (9:45 a.m. EDT), Zurich, Switzerland

UBS Global Life Sciences Conference
Presentation on September 20, 2010, at 7:30 a.m. EDT (1:30 p.m. CET),
New York, U.S.A.

The presentation will be available for download on Epigenomics
website: http://www.epigenomics.com/en/down_loads/corporate_material/

For further question please contact:

Dr. Achim Plum
Sen. VP. Corporate Development
Tel. +49 30 24 34 5 386
achim.plum@epigenomics.com

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development aim
at diagnosing cancer at an early stage before symptoms occur and
thereby may reduce mortality from this dreaded disease.

Epigenomics' product portfolio contains the CE-marked IVD test Epi
proColon, the world's first regulatory cleared molecular diagnostic
test for the detection of colorectal cancer in blood that is based on
the biomarker Septin9, and further proprietary DNA methylation
biomarkers and IVD products at various stages of development for
colorectal, lung and prostate cancer. For development and global
commercialization of IVD test products, Epigenomics pursues a dual
business strategy in which direct commercialization of proprietary
diagnostic test products is combined with non-exclusive licensing to
diagnostic industry players with broad customer access. Strategic
diagnostics industry partners include Abbott Molecular, Sysmex
Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories,
Inc. for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary,
Epigenomics Inc., in Seattle, WA, USA. For more information, please
visit Epigenomics' website at {www.epigenomics.com}[HYPERLINK:
http://www.epigenomics.com/].

Epigenomics legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale in the
United States of America. The analytical and clinical performance
characteristics of any product based on this technology which may be
sold at some future time in the USA have not been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade